Northrop Grumman begins delivery of critical assay technology to DHS for homeland defense applications

NewsGuard 100/100 Score

Northrop Grumman Corporation (NYSE:NOC) has begun deliveries of critical assay technology to the U.S. Department of Homeland Security (DHS) as part of the company's BioWatch Gen-3 contract to develop a new generation of biological detectors for homeland defense applications.

The assay represents the key technological component of Northrop Grumman's BioWatch Gen-3 system. BioWatch Gen-3 is envisioned by DHS as a fully autonomous network of bio-detectors located in population centers around the U.S. that will continuously monitor the air for agents of biological concern.

Under a Phase I indefinite delivery/indefinite quantity contract valued at $15.1 million awarded in November, Northrop Grumman's Advanced Concepts & Technologies Division is providing its Next-Gen Automated Detection Systems (NG-ADS) for independent laboratory and field testing at military and national laboratories. The intent is to demonstrate that the NG-ADS meets or exceeds performance criteria with regard to both detection and reporting.

"Automating the bio-detection process in these next generation instruments will provide much earlier warning of a bio-terrorism attack," said Dave Tilles, vice president of homeland defense programs at Northrop Grumman. "It will operate 24 hours per day, 365 days per year, in select cities across the nation. Earlier warning will allow the nation's public health and safety officials to reduce exposure, distribute medication sooner and proactively manage the response to a bio-threat."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Resveratrol can combat Alzheimer's via inflammatory suppression, study shows